title: The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization.
abstract: To evaluate the effects of various doses of subconjunctival bevacizumab injections in the treatment of patients with corneal neovascularization. During the 6-month-follow-up, no significant ocular or systemic adverse events were observed related to the subconjunctival bevacizumab injection. In Group 1, the total area of corneal neovascularization before injection was 14.8 ± 3.2 % of the corneal surface and 10.2 ± 2.8 % 6 months after injection (p < 0.01). The mean decrease in Group 1 was 32.0 ± 3.0 %. In Group 2, the total area of corneal neovascularization before and 6 months after the injection was 14.2 ± 2.5 and 9.8 ± 2.3 %, respectively (p < 0.01). The mean decrease in Group 2 was 31.0 ± 2.3 %. The difference between the two groups was not statistically significant (p > 0.05). Twenty-four eyes of 24 patients with corneal neovascularization who were treated with a subconjunctival injection of bevacizumab were included in this retrospective study. Fourteen eyes were treated with 2.5 mg/0.1 ml (Group 1), and 10 eyes were treated with 5.0 mg/0.2 ml (Group 2) of subconjunctival bevacizumab. Digital photographs of the cornea were used to determine the area of corneal neovascularization before injection and at 1 month, 3 months, and 6 months after treatment. Subconjunctival injection of bevacizumab is well tolerated and associated with a partial regression of corneal neovascularization. The efficacy of this treatment is not correlated to the injection dose.
authors: Haydarpasa Numune Education and Research Hospital, Ophthalmology Clinic, Tibbiye st., Uskudar, 34668, Istanbul, Turkey, torunbanu@yahoo.com.
authors: Banu Torun
authors: BT
authors: Acar
authors: Elvin
authors: E
authors: Halili
authors: Suphi
authors: S
authors: Acar
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000494:pharmacology; D000068258:Bevacizumab; D003228:Conjunctiva; D016510:Corneal Neovascularization / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D056965:Injections, Intraocular / Q000379:methods; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
references: Acta Ophthalmol. 2010 Dec;88(8):868-71
references: 19519730
references: Ophthalmology. 2005 Jun;112(6):1035-47
references: 15936441
references: Br J Ophthalmol. 2007 Jun;91(6):804-7
references: 17179168
references: Development. 1992 Feb;114(2):521-32
references: 1592003
references: Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1701-6
references: 19680676
references: Ophthalmology. 1994 Sep;101(9):1536-47
references: 8090456
references: Invest Ophthalmol Vis Sci. 1998 Jan;39(1):18-22
references: 9430540
references: Cornea. 2011 Feb;30(2):215-8
references: 20885312
references: Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1659-65
references: 18997093
references: Br J Ophthalmol. 2005 Oct;89(10):1368-70
references: 16170134
references: Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1625-32
references: 8675406
references: Clin Exp Ophthalmol. 2007 Nov;35(8):745-8
references: 17997779
references: J Cataract Refract Surg. 2007 Nov;33(11):1991-3
references: 17964413
references: Transplantation. 2008 Dec 27;86(12):1720-4
references: 19104411
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435
references: J Virol. 2001 Oct;75(20):9828-35
references: 11559816
references: Arch Ophthalmol. 1996 Aug;114(8):964-70
references: 8694732
references: Curr Opin Ophthalmol. 2001 Aug;12(4):242-9
references: 11507336
references: Ophthalmology. 2006 Mar;113(3):363-372.e5
references: 16458968
references: Invest Ophthalmol Vis Sci. 1994 Nov;35(12):3974-9
references: 7525506
references: Acta Ophthalmol. 2008 May;86(3):322-8
references: 17995975
references: Acta Ophthalmol Scand. 2004 Oct;82(5):557-63
references: 15453853
references: Cornea. 2008 Apr;27(3):349-52
references: 18362666
references: Cornea. 2008 Feb;27(2):142-7
references: 18216566
references: Am J Ophthalmol. 2008 Mar;145(3):424-431
references: 18207123
references: Cornea. 2000 Jul;19(4):526-33
references: 10928772
references: Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2514-22
references: 10937562
references: J Clin Oncol. 2003 Jan 1;21(1):60-5
references: 12506171
references: Ophthalmology. 2005 Jun;112(6):1048-53
references: 15885778
references: Acta Ophthalmol. 2009 Sep;87(6):653-8
references: 19021596
references: Graefes Arch Clin Exp Ophthalmol. 2007 Oct;245(10):1577-9
references: 17458556
references: Cornea. 1987;6(4):250-7
references: 2446823